secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2022-11-17T23:59:59+00:00
Accession:  0001711279-22-000064
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech subsidiary Jeune reports up to 9-month durability for KB301 in PEARL-1 extension
--------------------------------------------------------------------------------

- Up to nine months durability of effect observed in patients aged 55-76 following high dose KB301.
- Mean Subject Satisfaction Score change from baseline ranged from 1.6 to 1.85 points at 7-9 months.
- Responder rate 62-70% based on Subject Satisfaction Score ≥1 point change; Investigator Assessments showed clinically meaningful difference in 70-76% of treated cheeks.
- Plan to initiate Phase 2 PEARL-2 study in 1H 2023 for fine lines and wrinkles.
- All adverse events were injection-site related, transitory, mild or moderate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000064/0001711279-22-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000064/krys-20221117.htm
  HTML page:      https://secwatch.observer/filing/0001711279-22-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer